Pharmacovigilance Market to 2027 - Global Analysis and Forecasts by Clinical Trial Phase (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV), Service Provider (In-House and Contract Outsourcing), Type of Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining), End User (Hospitals, Research Organizations, and Pharmaceutical and Biotechnology Companies) and Geography
Report Code: TIPRE00003127 No. of Pages: 150 Category: Healthcare IT Status: Upcoming
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Pharmacovigilance plays a significant role in pharmaceutical and biotechnological sectors in designing of drugs and their interactions. The pharmacovigilance involves collecting information from healthcare providers and patients to know about the hazards associated with medications.
Increasing cases of adverse drug reactions and increasing consumption of drugs across the globe are expected to fuel the growth of the pharmacovigilance market during the forecast period. Moreover, shift in outsourcing of various activities among pharmaceutical and life science sector is anticipated to offer significant growth opportunities in the market.
The "Global Pharmacovigilance Market Analysis to 2027" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by clinical trial phase, service provider, type of method, end user and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading pharmacovigilance market players and offers key trends and opportunities in the market.
The global pharmacovigilance market is segmented on the basis of clinical trial phase, service provider, type of method, and end user. Based on clinical trial phase, the market is classified as, Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV. Similarly, on the basis of service type, the market is categorized as, in-house and contract outsourcing. The pharmacovigilance market is segmented based on type of method such as, spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. On the basis of end user, the market is classified as, hospitals, research organizations, and industrial.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global pharmacovigilance market based clinical trial phase, service provider, type of method, and end user. It also provides market size and forecast till 2027 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pharmacovigilance market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the pharmacovigilance market in the coming years, owing to the presence of major market players in the region along with the initiatives to reduce the healthcare expenditure as well as sophisticated healthcare infrastructure. Asia Pacific is anticipated to witness significant growth in the market during the forecast period, due to rising adoption of IT in the field of healthcare top offer better services to the patients.
The report analyzes factors affecting pharmacovigilance market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pharmacovigilance market in these regions.
The report also includes the profiles of key pharmacovigilance companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the pharmacovigilance market include, Accenture, Bristol-Myers Squibb Company, Linical Accelovance, Cognizant, Covance Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., ICON plc, Capgemini (IGATE Corporation), and Novartis AG among others.
Increasing cases of adverse drug reactions and increasing consumption of drugs across the globe are expected to fuel the growth of the pharmacovigilance market during the forecast period. Moreover, shift in outsourcing of various activities among pharmaceutical and life science sector is anticipated to offer significant growth opportunities in the market.
The "Global Pharmacovigilance Market Analysis to 2027" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by clinical trial phase, service provider, type of method, end user and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading pharmacovigilance market players and offers key trends and opportunities in the market.
The global pharmacovigilance market is segmented on the basis of clinical trial phase, service provider, type of method, and end user. Based on clinical trial phase, the market is classified as, Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV. Similarly, on the basis of service type, the market is categorized as, in-house and contract outsourcing. The pharmacovigilance market is segmented based on type of method such as, spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. On the basis of end user, the market is classified as, hospitals, research organizations, and industrial.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global pharmacovigilance market based clinical trial phase, service provider, type of method, and end user. It also provides market size and forecast till 2027 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pharmacovigilance market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the pharmacovigilance market in the coming years, owing to the presence of major market players in the region along with the initiatives to reduce the healthcare expenditure as well as sophisticated healthcare infrastructure. Asia Pacific is anticipated to witness significant growth in the market during the forecast period, due to rising adoption of IT in the field of healthcare top offer better services to the patients.
The report analyzes factors affecting pharmacovigilance market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pharmacovigilance market in these regions.
The report also includes the profiles of key pharmacovigilance companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the pharmacovigilance market include, Accenture, Bristol-Myers Squibb Company, Linical Accelovance, Cognizant, Covance Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., ICON plc, Capgemini (IGATE Corporation), and Novartis AG among others.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1. Pharmacovigilance Market- By Clinical Trial Phase
1.3.2. Pharmacovigilance Market- By Service Provider
1.3.3. Pharmacovigilance Market- By Type of Method
1.3.4. Pharmacovigilance Market- By End User
1.3.5. Pharmacovigilance Market- By Region
1.3.5.1. By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PHARMACOVIGILANCE MARKET LANDSCAPE
4.1. MARKET OVERVIEW
4.2. PEST ANALYSIS
4.2.1. North America - PEST Analysis
4.2.2. Europe - PEST Analysis
4.2.3. Asia Pacific - PEST Analysis
4.2.4. Middle East & Africa - PEST Analysis
4.2.5. South and Central America - PEST Analysis
5. PHARMACOVIGILANCE MARKET- KEY INDUSTRY DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PHARMACOVIGILANCE MARKET- GLOBAL ANALYSIS
6.1. PHARMACOVIGILANCE MARKET - GLOBAL MARKET OVERVIEW
6.2. PHARMACOVIGILANCE MARKET - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/ MARKET SHARE OF KEY PLAYERS
7. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY CLINICAL TRIAL PHASE
7.1. OVERVIEW
7.2. CLINICAL TRIAL PHASE MARKET FORECASTS AND ANALYSIS
7.3. PRE-CLINICAL MARKET
7.3.1. Overview
7.3.2. Pre-Clinical Market Forecast and Analysis (US$ Mn)
7.4. PHASE-I MARKET
7.4.1. Overview
7.4.2. Phase-I Market Forecast and Analysis (US$ Mn)
7.5. PHASE-II MARKET
7.5.1. Overview
7.5.2. Phase-II Market Forecast and Analysis (US$ Mn)
7.6. PHASE-III MARKET
7.6.1. Overview
7.6.2. Phase-III Market Forecast and Analysis (US$ Mn)
7.7. PHASE-IV MARKET
7.7.1. Overview
7.7.2. Phase-IV Market Forecast and Analysis (US$ Mn)
8. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY SERVICE PROVIDER
8.1. OVERVIEW
8.2. SERVICE PROVIDER MARKET FORECASTS AND ANALYSIS
8.3. IN-HOUSE MARKET
8.3.1. Overview
8.3.2. In-House Market Forecast and Analysis (US$ Mn)
8.4. CONTRACT OUTSOURCING MARKET
8.4.1. Overview
8.4.2. Contract Outsourcing Market Forecast and Analysis (US$ Mn)
9. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY TYPE OF METHOD
9.1. OVERVIEW
9.2. TYPE OF METHOD MARKET FORECASTS AND ANALYSIS
9.3. SPONTANEOUS REPORTING MARKET
9.3.1. Overview
9.3.2. Spontaneous Reporting Market Forecast and Analysis (US$ Mn)
9.4. INTENSIFIED ADR REPORTING MARKET
9.4.1. Overview
9.4.2. Intensified ADR Reporting Market Forecast and Analysis (US$ Mn)
9.5. TARGETED SPONTANEOUS REPORTING MARKET
9.5.1. Overview
9.5.2. Targeted Spontaneous Reporting Market Forecast and Analysis (US$ Mn)
9.6. COHORT EVENT MONITORING MARKET
9.6.1. Overview
9.6.2. Cohort Event Monitoring Market Forecast and Analysis (US$ Mn)
9.7. EHR MINING MARKET
9.7.1. Overview
9.7.2. EHR Mining Market Forecast and Analysis (US$ Mn)
10. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS MARKET
10.3.1. Overview
10.3.2. Hospitals Market Forecast and Analysis (US$ Mn)
10.4. RESEARCH ORGANIZATIONS MARKET
10.4.1. Overview
10.4.2. Research Organizations Market Forecast and Analysis (US$ Mn)
10.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET
10.5.1. Overview
10.5.2. Pharmaceutical and Biotechnology Companies Market Forecast and Analysis (US$ Mn)
11. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA PHARMACOVIGILANCE MARKET
11.1.1. North America Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.1.2. North America Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.3. North America Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.4. North America Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.5. North America Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.6. North America Pharmacovigilance Market Forecasts and Analysis - By Country
11.1.7. US Market Overview
11.1.7.1. US Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.7.2. US Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.7.3. US Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.7.4. US Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.8. Canada Market Overview
11.1.8.1. Canada Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.8.2. Canada Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.8.3. Canada Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.8.4. Canada Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.9. Mexico Market Overview
11.1.9.1. Mexico Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.9.2. Mexico Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.9.3. Mexico Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.9.4. Mexico Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2. EUROPE PHARMACOVIGILANCE MARKET
11.2.1. Europe Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.2.2. Europe Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.3. Europe Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.4. Europe Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.5. Europe Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.6. Europe Pharmacovigilance Market Forecasts and Analysis - By Country
11.2.7. UK Market Overview
11.2.7.1. UK Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.7.2. UK Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.7.3. UK Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.7.4. UK Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.8. Germany Market Overview
11.2.8.1. Germany Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.8.2. Germany Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.8.3. Germany Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.8.4. Germany Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.9. France Market Overview
11.2.9.1. France Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.9.2. France Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.9.3. France Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.9.4. France Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.10. Spain Market Overview
11.2.10.1. Spain Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.10.2. Spain Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.10.3. Spain Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.10.4. Spain Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.11. Italy Market Overview
11.2.11.1. Italy Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.11.2. Italy Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.11.3. Italy Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.11.4. Italy Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3. ASIA PACIFIC PHARMACOVIGILANCE MARKET
11.3.1. Asia Pacific Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.3.2. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.3. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Type (US$ Mn)
11.3.4. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.5. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.6. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Country
11.3.7. Japan Market Overview
11.3.7.1. Japan Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.7.2. Japan Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.7.3. Japan Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.7.4. Japan Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.8. China Market Overview
11.3.8.1. China Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.8.2. China Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.8.3. China Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.8.4. China Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.9. India Market Overview
11.3.9.1. India Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.9.2. India Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.9.3. India Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.9.4. India Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.10. Australia Market Overview
11.3.10.1. Australia Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.10.2. Australia Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.10.3. Australia Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.10.4. Australia Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.11. South Korea Market Overview
11.3.11.1. South Korea Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.11.2. South Korea Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.11.3. South Korea Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.11.4. South Korea Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4. MIDDLE EAST & AFRICA (MEA) PHARMACOVIGILANCE MARKET
11.4.1. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.4.2. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.3. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.4. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.5. Middle East and Africa Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.6. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Country
11.4.7. South Africa Market Overview
11.4.7.1. South Africa Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.7.2. South Africa Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.7.3. South Africa Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.7.4. South Africa Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.8. Saudi Arabia Market Overview
11.4.8.1. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.8.2. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.8.3. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.8.4. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.9. UAE Market Overview
11.4.9.1. UAE Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.9.2. UAE Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.9.3. UAE Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.9.4. UAE Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5. SOUTH AND CENTRAL AMERICA PHARMACOVIGILANCE MARKET
11.5.1. South and Central America Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.5.2. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Product (US$ Mn)
11.5.3. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.4. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.5. South and Central America Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5.6. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Country
11.5.7. Brazil Market Overview
11.5.7.1. Brazil Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.5.7.2. Brazil Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.7.3. Brazil Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.7.4. Brazil Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5.8. Argentina Market Overview
11.5.8.1. Argentina Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.5.8.2. Argentina Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.8.3. Argentina Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.8.4. Argentina Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
12. INDUSTRY LANDSCAPE
1.1. ORGANIC GROWTH STRATEGIES
1.1.1. New Product Launches
1.1.2. Marketing & Promotional Activities
1.2. INORGANIC GROWTH STRATEGIES
1.2.1. Partnerships, Collaborations, and Joint Ventures
1.2.2. Mergers & Acquisitions
13. PHARMACOVIGILANCE MARKET, KEY COMPANY PROFILES
13.1. ACCENTURE
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Financial Overview
13.1.4. Product Portfolio
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BRISTOL-MYERS SQUIBB COMPANY
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Financial Overview
13.2.4. Product Portfolio
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. LINICAL ACCELOVANCE
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Financial Overview
13.3.4. Product Portfolio
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. COGNIZANT
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Financial Overview
13.4.4. Product Portfolio
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. COVANCE INC. (LABORATORY CORPORATION OF AMERICA HOLDINGS)
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Financial Overview
13.5.4. Product Portfolio
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. F. HOFFMANN-LA ROCHE LTD.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Financial Overview
13.6.4. Product Portfolio
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. GLAXOSMITHKLINE PLC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Financial Overview
13.7.4. Product Portfolio
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ICON PLC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Financial Overview
13.8.4. Product Portfolio
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. CAPGEMINI (IGATE CORPORATION)
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Financial Overview
13.9.4. Product Portfolio
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. NOVARTIS AG
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Financial Overview
13.10.4. Product Portfolio
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1. Pharmacovigilance Market- By Clinical Trial Phase
1.3.2. Pharmacovigilance Market- By Service Provider
1.3.3. Pharmacovigilance Market- By Type of Method
1.3.4. Pharmacovigilance Market- By End User
1.3.5. Pharmacovigilance Market- By Region
1.3.5.1. By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PHARMACOVIGILANCE MARKET LANDSCAPE
4.1. MARKET OVERVIEW
4.2. PEST ANALYSIS
4.2.1. North America - PEST Analysis
4.2.2. Europe - PEST Analysis
4.2.3. Asia Pacific - PEST Analysis
4.2.4. Middle East & Africa - PEST Analysis
4.2.5. South and Central America - PEST Analysis
5. PHARMACOVIGILANCE MARKET- KEY INDUSTRY DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PHARMACOVIGILANCE MARKET- GLOBAL ANALYSIS
6.1. PHARMACOVIGILANCE MARKET - GLOBAL MARKET OVERVIEW
6.2. PHARMACOVIGILANCE MARKET - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/ MARKET SHARE OF KEY PLAYERS
7. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY CLINICAL TRIAL PHASE
7.1. OVERVIEW
7.2. CLINICAL TRIAL PHASE MARKET FORECASTS AND ANALYSIS
7.3. PRE-CLINICAL MARKET
7.3.1. Overview
7.3.2. Pre-Clinical Market Forecast and Analysis (US$ Mn)
7.4. PHASE-I MARKET
7.4.1. Overview
7.4.2. Phase-I Market Forecast and Analysis (US$ Mn)
7.5. PHASE-II MARKET
7.5.1. Overview
7.5.2. Phase-II Market Forecast and Analysis (US$ Mn)
7.6. PHASE-III MARKET
7.6.1. Overview
7.6.2. Phase-III Market Forecast and Analysis (US$ Mn)
7.7. PHASE-IV MARKET
7.7.1. Overview
7.7.2. Phase-IV Market Forecast and Analysis (US$ Mn)
8. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY SERVICE PROVIDER
8.1. OVERVIEW
8.2. SERVICE PROVIDER MARKET FORECASTS AND ANALYSIS
8.3. IN-HOUSE MARKET
8.3.1. Overview
8.3.2. In-House Market Forecast and Analysis (US$ Mn)
8.4. CONTRACT OUTSOURCING MARKET
8.4.1. Overview
8.4.2. Contract Outsourcing Market Forecast and Analysis (US$ Mn)
9. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY TYPE OF METHOD
9.1. OVERVIEW
9.2. TYPE OF METHOD MARKET FORECASTS AND ANALYSIS
9.3. SPONTANEOUS REPORTING MARKET
9.3.1. Overview
9.3.2. Spontaneous Reporting Market Forecast and Analysis (US$ Mn)
9.4. INTENSIFIED ADR REPORTING MARKET
9.4.1. Overview
9.4.2. Intensified ADR Reporting Market Forecast and Analysis (US$ Mn)
9.5. TARGETED SPONTANEOUS REPORTING MARKET
9.5.1. Overview
9.5.2. Targeted Spontaneous Reporting Market Forecast and Analysis (US$ Mn)
9.6. COHORT EVENT MONITORING MARKET
9.6.1. Overview
9.6.2. Cohort Event Monitoring Market Forecast and Analysis (US$ Mn)
9.7. EHR MINING MARKET
9.7.1. Overview
9.7.2. EHR Mining Market Forecast and Analysis (US$ Mn)
10. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - BY END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS MARKET
10.3.1. Overview
10.3.2. Hospitals Market Forecast and Analysis (US$ Mn)
10.4. RESEARCH ORGANIZATIONS MARKET
10.4.1. Overview
10.4.2. Research Organizations Market Forecast and Analysis (US$ Mn)
10.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET
10.5.1. Overview
10.5.2. Pharmaceutical and Biotechnology Companies Market Forecast and Analysis (US$ Mn)
11. PHARMACOVIGILANCE MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA PHARMACOVIGILANCE MARKET
11.1.1. North America Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.1.2. North America Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.3. North America Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.4. North America Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.5. North America Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.6. North America Pharmacovigilance Market Forecasts and Analysis - By Country
11.1.7. US Market Overview
11.1.7.1. US Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.7.2. US Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.7.3. US Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.7.4. US Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.8. Canada Market Overview
11.1.8.1. Canada Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.8.2. Canada Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.8.3. Canada Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.8.4. Canada Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.1.9. Mexico Market Overview
11.1.9.1. Mexico Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.1.9.2. Mexico Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.1.9.3. Mexico Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.1.9.4. Mexico Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2. EUROPE PHARMACOVIGILANCE MARKET
11.2.1. Europe Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.2.2. Europe Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.3. Europe Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.4. Europe Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.5. Europe Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.6. Europe Pharmacovigilance Market Forecasts and Analysis - By Country
11.2.7. UK Market Overview
11.2.7.1. UK Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.7.2. UK Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.7.3. UK Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.7.4. UK Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.8. Germany Market Overview
11.2.8.1. Germany Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.8.2. Germany Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.8.3. Germany Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.8.4. Germany Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.9. France Market Overview
11.2.9.1. France Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.9.2. France Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.9.3. France Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.9.4. France Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.10. Spain Market Overview
11.2.10.1. Spain Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.10.2. Spain Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.10.3. Spain Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.10.4. Spain Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.2.11. Italy Market Overview
11.2.11.1. Italy Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.2.11.2. Italy Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.2.11.3. Italy Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.2.11.4. Italy Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3. ASIA PACIFIC PHARMACOVIGILANCE MARKET
11.3.1. Asia Pacific Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.3.2. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.3. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Type (US$ Mn)
11.3.4. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.5. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.6. Asia Pacific Pharmacovigilance Market Forecasts and Analysis - By Country
11.3.7. Japan Market Overview
11.3.7.1. Japan Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.7.2. Japan Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.7.3. Japan Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.7.4. Japan Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.8. China Market Overview
11.3.8.1. China Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.8.2. China Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.8.3. China Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.8.4. China Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.9. India Market Overview
11.3.9.1. India Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.9.2. India Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.9.3. India Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.9.4. India Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.10. Australia Market Overview
11.3.10.1. Australia Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.10.2. Australia Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.10.3. Australia Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.10.4. Australia Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.3.11. South Korea Market Overview
11.3.11.1. South Korea Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.3.11.2. South Korea Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.3.11.3. South Korea Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.3.11.4. South Korea Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4. MIDDLE EAST & AFRICA (MEA) PHARMACOVIGILANCE MARKET
11.4.1. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.4.2. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.3. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.4. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.5. Middle East and Africa Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.6. Middle East & Africa (MEA) Pharmacovigilance Market Forecasts and Analysis - By Country
11.4.7. South Africa Market Overview
11.4.7.1. South Africa Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.7.2. South Africa Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.7.3. South Africa Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.7.4. South Africa Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.8. Saudi Arabia Market Overview
11.4.8.1. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.8.2. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.8.3. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.8.4. Saudi Arabia Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.4.9. UAE Market Overview
11.4.9.1. UAE Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.4.9.2. UAE Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.4.9.3. UAE Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.4.9.4. UAE Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5. SOUTH AND CENTRAL AMERICA PHARMACOVIGILANCE MARKET
11.5.1. South and Central America Pharmacovigilance Market Forecasts and Analysis (US$ Mn)
11.5.2. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Product (US$ Mn)
11.5.3. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.4. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.5. South and Central America Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5.6. South and Central America Pharmacovigilance Market Forecasts and Analysis - By Country
11.5.7. Brazil Market Overview
11.5.7.1. Brazil Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.5.7.2. Brazil Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.7.3. Brazil Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.7.4. Brazil Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
11.5.8. Argentina Market Overview
11.5.8.1. Argentina Pharmacovigilance Market Forecasts and Analysis - By Clinical Trial Phase (US$ Mn)
11.5.8.2. Argentina Pharmacovigilance Market Forecasts and Analysis - By Service Provider (US$ Mn)
11.5.8.3. Argentina Pharmacovigilance Market Forecasts and Analysis - By Type of Method (US$ Mn)
11.5.8.4. Argentina Pharmacovigilance Market Forecasts and Analysis - By End User (US$ Mn)
12. INDUSTRY LANDSCAPE
1.1. ORGANIC GROWTH STRATEGIES
1.1.1. New Product Launches
1.1.2. Marketing & Promotional Activities
1.2. INORGANIC GROWTH STRATEGIES
1.2.1. Partnerships, Collaborations, and Joint Ventures
1.2.2. Mergers & Acquisitions
13. PHARMACOVIGILANCE MARKET, KEY COMPANY PROFILES
13.1. ACCENTURE
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Financial Overview
13.1.4. Product Portfolio
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BRISTOL-MYERS SQUIBB COMPANY
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Financial Overview
13.2.4. Product Portfolio
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. LINICAL ACCELOVANCE
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Financial Overview
13.3.4. Product Portfolio
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. COGNIZANT
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Financial Overview
13.4.4. Product Portfolio
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. COVANCE INC. (LABORATORY CORPORATION OF AMERICA HOLDINGS)
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Financial Overview
13.5.4. Product Portfolio
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. F. HOFFMANN-LA ROCHE LTD.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Financial Overview
13.6.4. Product Portfolio
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. GLAXOSMITHKLINE PLC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Financial Overview
13.7.4. Product Portfolio
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ICON PLC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Financial Overview
13.8.4. Product Portfolio
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. CAPGEMINI (IGATE CORPORATION)
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Financial Overview
13.9.4. Product Portfolio
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. NOVARTIS AG
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Financial Overview
13.10.4. Product Portfolio
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Accenture
2. Bristol-Myers Squibb Company
3. Linical Accelovance
4. Cognizant
5. Covance Inc.
6. F. Hoffmann-La Roche Ltd.
7. GlaxoSmithKline plc.
8. ICON plc
9. Capgemini (IGATE Corporation)
10. Novartis AG
1. Accenture
2. Bristol-Myers Squibb Company
3. Linical Accelovance
4. Cognizant
5. Covance Inc.
6. F. Hoffmann-La Roche Ltd.
7. GlaxoSmithKline plc.
8. ICON plc
9. Capgemini (IGATE Corporation)
10. Novartis AG